Published on July 13, 2010 at 7:21 AM
AlphaRx, Inc. (OTCBB: ALRX) announced positive preclinical results of GAI-122 injectable nanoemulsion, a Mitochondria-targeted neuroprotective drug candidate being developed for the treatment of Acute Ischemic Stroke. The results will be delivered as a podium presentation during the 37th Annual Meeting and Exposition of the Controlled Release Society in Portland, Oregon July 10 - 14, 2010.
On Wednesday, July 14, 2010, Dr. Joseph Schwarz, Chief Scientist of AlphaRx, will make an oral podium presentation of GAI-122 injectable nanoemulsion for neuroprotection. The results conclude that, based on the neuroprotective properties of GAI-122 and the increased concentration of GAI-122 in the brain after parenteral delivery relative to oral dosing, it is reasonable to expect that an injectable form of GAI-122 based on a nanoemulsion, will provide the required protection against damage to cognitive and behavioral functions in humans experiencing various ischemic disorders.
SOURCE AlphaRx Inc.